Ebola Outbreak Africa: Nigeria Becomes Fifth Country
Ebola outbreak Africa update: Nigeria confirms an imported case in Abuja, the fifth country affected. What WHO says and what is still unknown.
Read More
Bepirovirsen FDA Approval: GSK, Ionis and the Market
Bepirovirsen FDA approval gives GSK a first-in-class hepatitis B drug. See the designations, Ionis royalties, companion test and what is undisclosed.
GLP-1 Beauty Market: Brands Test Skin-Change Products
GLP-1 beauty market: L’Oréal, Natura and Galderma are testing products for weight-loss skin changes. See the forecasts and open questions.
Toripalimab India Approval: Dr Reddy’s Second Indication
Toripalimab India approval: Dr. Reddy’s adds esophageal cancer to Zytorvi’s label. What the data show and what price and launch details are missing.
Measles Vaccination: What 4,410 US Cases Mean for Families
Measles vaccination guidance as US cases hit 4,410: CDC says two MMR doses are 97% effective. What Pennsylvania and the CDC advise families.
Gilead Ulcerative Colitis Drug: Phase 3 Planned for 2027
Gilead ulcerative colitis drug emvistegrast met its Phase 2 goal; Phase 3 is planned for 2027 and combinations are in view. What is and is not known.
Cardiovascular Medical Devices: Haemonetics Bets on Closure
Cardiovascular medical devices: Haemonetics wins an FDA decision for PerQseal Elite. What it signals about strategy, and what is not disclosed.
Real-World Healthcare Data: AstraZeneca-Oracle Privacy Test
Real-world healthcare data under AstraZeneca and Oracle: what deidentified means, what governance is promised, and what is undisclosed.
Biotechnology IPO 2026: Lycia Eyes $265M, Faces Big Risks
Biotechnology IPO 2026: Lycia Therapeutics eyes up to $264.6M. What the money funds, the runway and the risks in the filing.